Loading…
Editas Medicine, Inc. is projected to rise to $4.60 by 2027, a +29% move from its current price of $3.57. EDIT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.39 | $3.57 | $3.76 | +0.08% |
| May 30 | $3.32 | $3.58 | $3.85 | +0.17% |
| May 31 | $3.27 | $3.58 | $3.91 | +0.25% |
| Jun 1 | $3.23 | $3.58 | $3.97 | +0.33% |
| Jun 2 | $3.19 | $3.58 | $4.02 | +0.41% |
| Jun 3 | $3.16 | $3.59 | $4.07 | +0.50% |
| Jun 4 | $3.13 | $3.59 | $4.12 | +0.58% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.13 | $3.59 | $4.12 | +0.58% |
| Week 2 | $2.98 | $3.61 | $4.38 | +1.16% |
| Week 3 | $2.87 | $3.63 | $4.60 | +1.75% |
| Week 4 | $2.78 | $3.65 | $4.80 | +2.34% |
| Week 5 | $2.71 | $3.67 | $4.99 | +2.94% |
| Week 6 | $2.64 | $3.70 | $5.17 | +3.53% |
| Week 7 | $2.59 | $3.72 | $5.34 | +4.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Editas Medicine, Inc. is a healthcare company focused on developing transformative genomic medicines using a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia, and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease.
Editas Medicine was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine was incorporated in 2013 and is based in Cambridge, Massachusetts.
Editas Medicine, Inc. (EDIT) operates in the Healthcare sector as a clinical stage genome editing company focused on developing genomic medicines.
The current price is $3.57, and its market capitalization is $547.86M. The stock is ranked 2941 by market capitalization.
Forecasts indicate a bullish price outlook over the coming years. The projected 2026 average price is $3.57, rising to $4.60 in 2027, $8.72 in 2030, $26.76 in 2040, and $43.68 in 2050. Max projections reach $57.96 in 2040 and $100.47 in 2050, with a long-run ROI of 1123.6% by 2050.
A major floor 53.4% below — a decisive break under it would weaken the trend.
The nearest floor, 31.1% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 20.7% above — clearing it would confirm fresh momentum.
Key EDIT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EDIT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.94 | Buy | $3.07 | Buy |
| MA 10 | $2.80 | Buy | $2.94 | Buy |
| MA 20 | $2.91 | Buy | $2.91 | Buy |
| MA 50 | $2.84 | Buy | $2.81 | Buy |
| MA 100 | $2.46 | Buy | $2.67 | Buy |
| MA 200 | $2.66 | Buy | $2.61 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.38 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 228.14 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 14.79 | Buy |
| Bollinger %B (20,2) | 1.16 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.12 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 74.62 | Sell |
| Momentum (10) | 0.64 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 3.16 | Buy |
| ADX (14) | 17.26 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 indicating strong momentum.
The stock trades above the 50-day simple moving average at $2.84 and the 200-day simple moving average at $2.66. Immediate support is at $2.46 and resistance at $3.57. The 30-day price range spans from a low of $2.54 to a high of $5.02.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.66 | $3.57 | $4.87 | 0% | Neutral | |
| $3.33 | $4.60 | $6.87 | +29% | Bullish | |
| $4.11 | $6.00 | $9.50 | +68% | Bullish | |
| $5.37 | $8.25 | $13.69 | +131% | Bullish | |
| $5.44 | $8.72 | $15.04 | +144% | Bullish | |
| $5.19 | $8.69 | $15.50 | +143% | Bullish | |
| $5.70 | $9.93 | $18.24 | +178% | Bullish | |
| $5.62 | $10.17 | $19.17 | +185% | Bullish | |
| $7.18 | $13.48 | $26.05 | +278% | Bullish | |
| $8.96 | $17.46 | $34.49 | +389% | Bullish | |
| $12.04 | $26.76 | $57.96 | +650% | Bullish | |
| $19.66 | $43.68 | $100.47 | +11.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.66 | $3.57 | $4.29 | +0.00% |
| June 2026 | $3.26 | $3.91 | $4.84 | +9.42% |
| July 2026 | $3.16 | $3.85 | $4.89 | -1.45% |
| August 2026 | $3.06 | $3.78 | $4.89 | -1.94% |
| September 2026 | $3.16 | $3.93 | $5.17 | +4.18% |
| October 2026 | $3.09 | $3.89 | $5.18 | -1.20% |
| November 2026 | $2.83 | $3.59 | $4.84 | -7.69% |
| December 2026 | $2.79 | $3.57 | $4.87 | -0.47% |
Click any year to see its month-by-month EDIT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EDIT to range from $1.66 to $4.87 through 2026. The $3.57 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The EDIT price prediction for 2027 points to an average of $4.60 (low $3.33, high $6.87) — a potential gain of +29% on today's $3.57. Momentum favours further upside here.
In 2028, EDIT is projected to trade between $4.11 and $9.50, averaging $6.00 — a potential gain of +68% from today's $3.57. That is up +30% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Editas Medicine, Inc.'s 2029 outlook centres on $8.25, within a $5.37 to $13.69 range. That is up +37% on the projected 2028 average. That marks a +131% change versus current levels. Momentum favours further upside here.
By 2030, EDIT could reach as high as $15.04, with a base case around $8.72 and support toward $5.44 — roughly +144% from $3.57. Buyers look set to stay in control over this stretch.
Expect EDIT to range from $5.19 to $15.50 through 2031. The $8.69 average target implies a +143% move from current prices. That is 0% versus the projected 2030 average. Momentum favours further upside here.
The EDIT price prediction for 2032 points to an average of $9.93 (low $5.70, high $18.24) — a potential gain of +178% on today's $3.57. Buyers look set to stay in control over this stretch.
In 2033, EDIT is projected to trade between $5.62 and $19.17, averaging $10.17 — a potential gain of +185% from today's $3.57. That is up +2% on the projected 2032 average. Momentum favours further upside here.
Editas Medicine, Inc.'s 2034 outlook centres on $13.48, within a $7.18 to $26.05 range. That is up +33% on the projected 2033 average. That marks a +278% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, EDIT could reach as high as $34.49, with a base case around $17.46 and support toward $8.96 — roughly +389% from $3.57. Momentum favours further upside here.
Expect EDIT to range from $12.04 to $57.96 through 2040. The $26.76 average target implies a +650% move from current prices. That is up +53% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The EDIT price prediction for 2050 points to an average of $43.68 (low $19.66, high $100.47) — a potential gain of +11.2x on today's $3.57. Momentum favours further upside here.
Investing $1,000 in EDIT today (≈ 280.112045 EDIT) could be worth
$12,235.8
+$11,235.8 (+1124%) by 2050 · US Dollar
Based on the average projected EDIT price of $43.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EDITwould be worth at today's price.
$1,000 invested in EDIT on May 27, 2025 (≈ 606.060615 EDIT) would be worth
$2,163.64
+$1,163.64 (+116.4%) today · 2.16× · US Dollar
Based on a EDIT entry price of $1.65 vs. today's $3.57.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.6 | $1,373.08 | +37.3% |
| 1 month ago | $2.89 | $1,235.29 | +23.5% |
| 3 months ago | $2.18 | $1,637.61 | +63.8% |
| 6 months ago | $2.41 | $1,481.33 | +48.1% |
| 1 year ago | $1.65 | $2,163.64 | +116.4% |
| All time (5.0y) ago | $34.22 | $104.32 | -89.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EDIT forecast.
Our base-case forecast reaches $7.10 around 2029.
Implied market cap at $7.10: $1.09B
The multi-year forecast points to a bullish trajectory with rising averages and substantial upside potential through 2050. The 2030 average price is $8.72, with a max of $15.04 and a min of $5.44, yielding a 144.4% ROI in that year. By 2040 the average is projected at $26.76 with a max of $57.96 and a min of $12.04, and a 649.7% ROI.
In 2050 the average is $43.68, the max $100.47, the min $19.66, and the ROI reaches 1123.6%. The forecast consistently shows bullish sentiment from 2027 onward. However, the asset also exhibits high volatility, as indicated by an annualized volatility of 100%, underscoring the risk of large price swings despite the upside potential.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $8.72 with a min of $5.44 and a max of $15.04, and a 144.4% ROI with bullish sentiment. These are estimates, not guarantees.
Forecasts indicate a bullish trajectory from 2027 onward, with average prices rising to $8.72 by 2030, $26.76 by 2040, and $43.68 by 2050, and ROIs of 144.4%, 649.7%, and 1123.6% respectively. 2026 shows a neutral view with an average of $3.57. These are estimates, not guarantees.
The max forecast for 2050 is $100.47, with an average of $43.68 and a min of $19.66, corresponding to a 1123.6% ROI. These are projections, not guarantees.
The current price is $3.57 and the market capitalization is $547.86M. The stock rank is 2941.
The 30-day range is from $2.54 to $5.02.
Editas Medicine, Inc. Community Discussion
0Share your Editas Medicine, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.